Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4928300 | 1.00 | KMT2A (0.33) | KMT2AL3MBTL1NR1H4BACE1KDM4E | |
| SCHEMBL4928283 | 1.00 | KMT2A (0.33) | KMT2AL3MBTL1NR1H4BACE1KDM4E | |
| SCHEMBL4928289 | 1.00 | KMT2A (0.33) | KMT2AL3MBTL1NR1H4BACE1KDM4E | |
| SCHEMBL4918344 | 0.90 | BACE1 (0.32) | KMT2ABACE1 | |
| SCHEMBL4918332 | 0.90 | BACE1 (0.32) | KMT2ABACE1 | |
| SCHEMBL4918339 | 0.90 | BACE1 (0.32) | KMT2ABACE1 | |
| SCHEMBL4918349 | 0.90 | BACE1 (0.32) | KMT2ABACE1 | |
| SCHEMBL4923022 | 0.83 | BACE1 (0.35) | BACE1 | |
| SCHEMBL4923027 | 0.83 | BACE1 (0.35) | BACE1 | |
| SCHEMBL4923021 | 0.83 | BACE1 (0.35) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015238-A1 | CYCLOALKYLMETHOXY-SUBSTITUTED ACETIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-17 | — | — | US | disclosed |
| US-7259177-B2 | Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-21 | — | — | US | disclosed |
| US-7173151-B2 | Cycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTISDEUTSCHAND GMBH (DE) | 2007-02-06 | — | — | US | disclosed |
| US-20050101637-A1 | Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-05-12 | — | — | US | disclosed |
| US-20040220261-A1 | Cycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015238-A1 | CYCLOALKYLMETHOXY-SUBSTITUTED ACETIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | GPR119, PC, ACADM | KMT2A 4433/4885L3MBTL1 4518/4885NR1H4 351/4885 |
| US-20040220261-A1 | Cycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals | GPR119, FFAR1, FASN | KMT2A 4435/4885L3MBTL1 4050/4885NR1H4 441/4885 |
| US-20050101637-A1 | Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals | GPR119, PC, CPT1A | KMT2A 4494/4885L3MBTL1 4572/4885NR1H4 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.